Skip to main content
OpenTrials
Completed

NCT Number: NCT00603187

ACY-7 Oral Administration of Acyline

We propose oral dosing of gastrointestinal permeation enhancement technology [GIPET] enhanced oral acyline at 20 mg everyday for one week to determine the steady-state (multiple-dose) pharmacokinetics of oral acyline in four normal, healthy young men.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

University of Washington

Seattle, Washington, 98195, United States

About this study

The purpose of this study is to test how the body responds to a new oral form of acyline given for seven days and to also look at the safety of oral acyline.

Acyline temporarily blocks the production of the hormone testosterone in healthy men. It has been tested in over 100 men in an injection form. This study will be testing acyline in a pill form for seven days.

This study may help develop an oral form of testosterone-blocker which may be useful in the treatment of diseases such as prostate cancer, premature puberty and possibly in a male contraceptive.

This study will evaluate a single dose of oral acyline given once a day for seven days and subsequent effects on Testosterone, FSH and LH blood serum concentrations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male
  • 18-50 years of age
  • Non-smoker
  • Not taking any medications other than the study drug for the duration of the study.
  • Must be willing to use an accepted method of contraception during the study.

Exclusion criteria

  • BMI > 35
  • Abnormal evaluation on screening exam and labs
  • Known history of alcohol abuse, illicit drugs or steroids and/or use of more that 3 alcoholic beverages/day
  • History of current testosterone use or infertility
  • History of testicular disease or severe testicular trauma
  • History of major psychiatric disorder or sleep apnea
  • History of bleeding disorder or need for anticoagulation
  • Current smoker or utilizing nicotine patches or gum
  • Participation in a hormonal drug study within past month.

Treatment and study plan

Acyline

Drug

20 mg GIPET enhanced oral dose, daily for 7-days

Primary outcomes

  1. Testosterone Blood Serum Concentration

    Time frame: 7 days

    Blood for measurement of serum testosterone was obtained prior to the 1st, 5th and 6th dose of GIPET™-enhanced oral acyline and 0.5,1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 60 hours after the 7th dose.

Secondary outcomes

  1. FSH Blood Serum Concentration

    Time frame: 7 days

    Blood for measurement of serum follicle stimulating hormone concentrations was obtained prior to the 1st, 5th and 6th dose of GIPET™-enhanced oral acyline and 0.5,1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 60 hours after the 7th dose.

  2. LH Blood Serum Concentration

    Time frame: 7 days

    Blood for measurement of serum leutenizing hormone concentrations was obtained prior to the 1st, 5th and 6th dose of GIPET™-enhanced oral acyline and 0.5,1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 60 hours after the 7th dose.

Sponsors and collaborators

Lead sponsor

University of Washington

Other

Collaborators

  • Merrion Pharmaceuticals, LLC

Registry information

Official study title

Oral Administration of the GnRH Antagonist Acyline in Normal Men Part II: Multiple-dose Pharmacokinetics (Acyline-7/MER 104-02)

Acronym: ACY-7

Important dates

Study start
2008
Primary completion
2008
Study completion
2008
First posted
Jan 28, 2008
Registry last updated
Jun 9, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.